Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | IL1B | P01584 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20272422 | 0.80 | SLC2A1 (0.47) | HTTPTK2SLC2A1FGFR1MAPT | |
| SCHEMBL10803369 | 0.77 | SLC2A1 (0.44) | HTTPTK2SLC2A1MAPTALDH1A1 | |
| SCHEMBL6850243 | 0.77 | SLC2A1 (0.44) | HTTPTK2SLC2A1MAPTL3MBTL1 | |
| SCHEMBL9069485 | 0.76 | MAPT (0.42) | HTTPTK2SLC2A1FGFR1MAPT | |
| SCHEMBL24121744 | 0.74 | HTT (0.44) | HTTPTK2SLC2A1FGFR1MAPT | |
| SCHEMBL30304804 | 0.74 | HTT (0.44) | HTTPTK2SLC2A1FGFR1MAPT | |
| SCHEMBL10840609 | 0.74 | L3MBTL1 (0.59) | HTTSLC2A1MAPTL3MBTL1 | |
| SCHEMBL18879034 | 0.74 | SLC2A1 (0.56) | HTTPTK2SLC2A1MAPTL3MBTL1 | |
| SCHEMBL8423993 | 0.73 | HTT (0.42) | HTTPTK2SLC2A1MAPTALDH1A1 | |
| SCHEMBL10840466 | 0.72 | SLC2A1 (0.70) | HTTSLC2A1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652035-B2 | CRF receptor antagonists and methods relating thereto | Neurocrine Bioscience, Inc. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652035-B2 | CRF receptor antagonists and methods relating thereto | Neurocrine Bioscience, Inc. (US) | 2010-01-26 | — | — | US | disclosed |
| EP-1802621-B1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | SMITHKLINE BEECHAM CORK LTD (IE) | 2009-05-06 | — | — | EP | disclosed |
| US-20080064719-A1 | Crf Receptor Antagonists And Methods Relating Thereto | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064719-A1 | Crf Receptor Antagonists And Methods Relating Thereto | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2008-03-13 | — | — | US | disclosed |
| US-20040157851-A1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-08-12 | — | — | US | disclosed |
| US-20040087589-A1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-05-06 | — | — | US | disclosed |
| US-6531475-B1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2003-03-11 | — | — | US | disclosed |
| US-6514982-B1 | Corticotropin releasing factor is believed to be the major physiological regulator of the basal and stress-release of adrenocorticotropic hormone, beta -endorphin, and other pro-opiomelanocortin-derived peptides from the pituitary | NEUROCRINE BIOSCIENCES, INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1129091-B1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2002-10-02 | — | — | EP | disclosed |
| EP-1129091-A2 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | Neurocrine Biosciences, Inc. (US) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027846-A2 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064719-A1 | Crf Receptor Antagonists And Methods Relating Thereto | CRHR1, CRHR2, SCTR | HTT 946/4885PTK2 4477/4885SLC2A1 760/4885 |
| US-20040157851-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, CRHR2, MC2R | HTT 1638/4885PTK2 4321/4885SLC2A1 609/4885 |
| US-20040087589-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, CRHR2, MC2R | HTT 1638/4885PTK2 4321/4885SLC2A1 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.